Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | F13A1 | P00488 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14043307 | 0.86 | KDM4E (0.58) | KDM4EMAPK1HIF1ATSHRALDH1A1 | |
| SCHEMBL21452490 | 0.86 | KDM4E (0.65) | KDM4EMAPK1HIF1ATSHRALDH1A1 | |
| SCHEMBL19750417 | 0.84 | KDM4E (0.70) | KDM4EMAPK1HIF1ATSHRALDH1A1 | |
| SCHEMBL18346903 | 0.84 | KDM4E (0.70) | KDM4EMAPK1HIF1ATSHRALDH1A1 | |
| SCHEMBL21449037 | 0.82 | EPHX1 (0.41) | TP53BP1MAPTRAB9A | |
| SCHEMBL24109302 | 0.81 | KDM4E (0.46) | KDM4EMAPK1HIF1ATSHRALDH1A1 | |
| SCHEMBL8107 | 0.81 | KDM4E (0.71) | KDM4EMAPK1HIF1ATSHRALDH1A1 | |
| SCHEMBL354240 | 0.80 | CYP2D6 (0.37) | KDM4ETSHRALDH1A1TP53BP1MAPT | |
| SCHEMBL26810733 | 0.79 | MEN1 (0.44) | KDM4EMAPK1HIF1ATSHRALDH1A1 | |
| SCHEMBL24999173 | 0.78 | TSHR (0.34) | TSHRMTNR1ATP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834412-B2 | Derivatives of aryl hydrocarbon receptor agonists | AZORA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230227408-A1 | DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTS | AZORA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11685722-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-7429574-B2 | 4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7384937-B2 | Fused heterocyclic compounds and use thereof | BRISTOL-MYERS SQUIBB CO. (US) | 2008-06-10 | — | — | US | disclosed |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-7288571-B2 | Thyroid receptor ligands and method II | KARO BIO AB (SE) | 2007-10-30 | — | — | US | disclosed |
| US-7288571-B2 | Thyroid receptor ligands and method II | KARO BIO AB (SE) | 2007-10-30 | — | — | US | disclosed |
| WO-2007067537-A1 | PYRROLOPYRIDINE KINASE INHIBITING COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-6680324-B2 | 4-AMINO-6-PHENYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227408-A1 | DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTS | AHR, ARNT, NR4A1 | KDM4E 1250/4885MAPK1 1875/4885HIF1A 921/4885 |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | KDM4E 4070/4885MAPK1 11/4885HIF1A 2571/4885 |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | KDM4E 502/4885MAPK1 3668/4885HIF1A 1044/4885 |
| US-11834412-B2 | Derivatives of aryl hydrocarbon receptor agonists | AHR, ARNT, NR4A1 | KDM4E 1250/4885MAPK1 1875/4885HIF1A 921/4885 |
| US-11685722-B2 | Inhibition of Olig2 activity | GLI2, ING2, GMFG | KDM4E 2547/4885MAPK1 2001/4885HIF1A 839/4885 |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | KDM4E 2935/4885MAPK1 56/4885HIF1A 2029/4885 |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | KDM4E 4390/4885MAPK1 2298/4885HIF1A 393/4885 |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | KRAS, NRAS, BRAF | KDM4E 4039/4885MAPK1 81/4885HIF1A 3229/4885 |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | BMX, ERBB2, FRK | KDM4E 1133/4885MAPK1 308/4885HIF1A 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.